Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice

Gadde, Kishore M.

doi:10.1517/14656566.2014.890590

Cited by 23 publications

(18 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obesity is a chronic condition that cannot be ameliorated simply with lifestyle behavior alone [1,2]. Obesity contributes to insulin resistance, type 2 diabetes (T2DM) and is associated with a host of comorbidities and therefore represents a healthcare crisis.…”

Section: Introductionmentioning

confidence: 99%

Testosterone and weight loss

Traish

2014

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

Purpose of reviewThe purpose of this article is to examine the contemporary data linking testosterone therapy in overweight and obese men with testosterone deficiency to increased lean body mass, decreased fat mass, improvement in overall body composition and sustained weight loss. This is of paramount importance because testosterone therapy in obese men with testosterone deficiency represents a novel and a timely therapeutic strategy for managing obesity in men with testosterone deficiency.Recent findingsLong-term testosterone therapy in men with testosterone deficiency produces significant and sustained weight loss, marked reduction in waist circumference and BMI and improvement in body composition. Further, testosterone therapy ameliorates components of the metabolic syndrome. The aforementioned improvements are attributed to improved mitochondrial function, increased energy utilization, increased motivation and vigor resulting in improved cardio-metabolic function and enhanced physical activity.SummaryThe implication of testosterone therapy in management of obesity in men with testosterone deficiency is of paramount clinical significance, as it produces sustained weight loss without recidivism. On the contrary, alternative therapeutic approaches other than bariatric surgery failed to produce significant and sustained outcome and exhibit a high rate of recidivism. These findings represent strong foundations for testosterone therapy in obese men with testosterone deficiency and should spur clinical research for better understanding of usefulness of testosterone therapy in treatment of underlying pathophysiological conditions of obesity.

show abstract

Section: Introductionmentioning

confidence: 99%

Testosterone and weight loss

Traish

2014

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

show abstract

“…To add complexity in drug development in this therapeutic area, it has been reported that numerous methodological problems limit the interpretation of clinical trial data and their generalizability [199]. Moreover, the landscape of antiobesity drugs is also hampered by the reduced effect of antiobesity drugs outside clinical trials with respect to that exerted in a clinical trial setting, with a behavioral and dietetic support [189].…”

Section: Targetmentioning

confidence: 99%

New Perspectives on the Development of Antiobesity Drugs

Costantino

Barlocco

2015

Future Med. Chem.

View full text Add to dashboard Cite

After many years of research, obesity is still a disease with an unmet medical need. Very few compounds have been approved, acting mainly on neuromediators; researches, in recent years, pointed toward compounds potentially safer than first-generation antiobesity drugs, able to interact with one or more (multitarget therapy) receptors for substances produced by the gut, adipose tissue and other targets outside CNS. Other holistic approaches, such as those involving gut microbiota and plant extracts, appeared recently in the literature, and undoubtedly will contribute to the discovery of a valuable therapy for this disease. This review deals with the positive results and the pitfalls obtained following these approaches, with a view on their clinical trial studies.

show abstract

“…The most effective currently available anti-obesity drug phentermine/topiramate combination therapy has the severe teratogenic risk of cleft lip with or without cleft palate. 42 Women are required to have a negative pregnancy test prior to taking the drug, but should also use highly effective contraceptives. 42 …”

Section: Bariatric Surgerymentioning

confidence: 99%

“…42 Women are required to have a negative pregnancy test prior to taking the drug, but should also use highly effective contraceptives. 42 …”

Section: Bariatric Surgerymentioning

confidence: 99%